As with all current targeted cancer therapeutics, MEKi efficacy is limited by innate and acquired resistance and we have contributed to the understanding of both modes of MEKi resistance in colorectal cancer (CRC) cells, where BRAF and KRAS mutations are common oncogenic drivers. Here, KRAS is linked to colorectal carcinoma.